Meeting
2022 ASCO Annual Meeting
Phase I open-label single arm study of GPRC5D CAR T-cells (OriCAR-017) in patients with relapsed/refractory multiple myeloma (POLARIS).
Presenter
He Huang
Department of Hematology, The First Affliated Hospital, Zhejiang University;
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT05016778
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8004)
DOI
10.1200/JCO.2022.40.16_suppl.8004
Abstract #
8004
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2023 ASCO Annual Meeting
Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM).
Speaker: Juan Du, MD, PhD
Videos & Slides
2023 ASCO Annual Meeting
A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CAMMOUFLAGE trial).
Speaker: Jesus G. Berdeja, MD
Videos & Slides
2020 ASCO Virtual Scientific Program
Open-label pilot study of genetically engineered NY-ESO-1–specific t cells (GSK3377794) alone or in combination with pembrolizumab in relapsed/refractory multiple myeloma.
Speaker: Aaron Rapoport, MD
Videos & Slides
2024 ASCO Annual Meeting
OriCAR-017, a novel GPRC5D-targeting CAR-T, in patients with relapsed/refractory multiple myeloma: Long term follow-up results of phase 1 study (POLARIS).
Speaker: Shan Fu